Russia continues to see active ingredients shortages for its pharma sector

Russia is still experiencing a shortage of active ingredients for its pharmaceutical sector due to a low interest of local producers in the establishment of their own production, despite the support that has been provided to the industry by the state in recent years, reports The Pharma Letter’s local correspondent.

With the beginning of war in Ukraine, the Russian pharmaceutical industry faced serious problems with the imports of raw materials that, in turn, led to higher prices for drugs. This prompted the state to increase support of domestic producers of active ingredients.

As part of this, manufacturers were promised new support in the form of preferential loans and priority access to governmental procurements. However, most companies are not yet in a hurry to take advantage of this help. They are also concerned about the lack of mass production of many chemical components in the Russian Federation. Market participants also doubt about prospects of competition with leaders such as China and India, which continue to dominate in the local market.